These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12902858)

  • 1. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
    Evans JF
    Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
    Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
    Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
    Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
    Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
    Chau I; Cunningham D
    N Engl J Med; 2002 Apr; 346(14):1085-7. PubMed ID: 11932478
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
    Ahuja N; Singh A; Singh B
    J Pharm Pharmacol; 2003 Jul; 55(7):859-94. PubMed ID: 12906745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive.
    Lew JI; Guo Y; Kim RK; Vargish L; Michelassi F; Arenas RB
    J Gastrointest Surg; 2002; 6(4):563-8. PubMed ID: 12127122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
    Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
    J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cyclooxygenases in inflammation, cancer, and development.
    Williams CS; Mann M; DuBois RN
    Oncogene; 1999 Dec; 18(55):7908-16. PubMed ID: 10630643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
    Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
    Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.
    Sánchez-Fidalgo S; Martín-Lacave I; Illanes M; Motilva V
    Eur J Pharmacol; 2004 Nov; 505(1-3):187-94. PubMed ID: 15556152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Schwartz JI; Chan CC; Mukhopadhyay S; McBride KJ; Jones TM; Adcock S; Moritz C; Hedges J; Grasing K; Dobratz D; Cohen RA; Davidson MH; Bachmann KA; Gertz BJ
    Clin Pharmacol Ther; 1999 Jun; 65(6):653-60. PubMed ID: 10391671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
    Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
    Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.